Psychedelics For Chronic Pain uk : What The Science Says

Chronic pain is an unwelcome companion for millions of people worldwide, often leading to a reduced quality of life and debilitating side effects from conventional pain medications, including addiction.  Additionally, the mental toll of chronic pain cannot be overlooked, with many sufferers grappling with depression, anxiety, and substance abuse as a result.Psychedelics For Chronic Pain uk

In the pursuit of alternative approaches to managing chronic pain, a recent survey study conducted by The Beckley Foundation in collaboration with Maastricht University has unveiled intriguing insights. This study sheds light on the potential of classical psychedelics, such as psilocybin and LSD, to alleviate pain in specific conditions like fibromyalgia and arthritis.

psychedelic uk for chronic pain suffer

The Beckley Foundation performed a comprehensive survey of chronic pain sufferers on their experiences with psychedelic usage, comparing the efficacy of conventional therapy, full psychedelic doses, and microdoses.

The study analysed data from various conditions, including fibromyalgia, arthritis, migraine, tension-type headache, and sciatica.

The survey results revealed that participants reported superior pain relief with psychedelics compared to conventional medication, except in the case of sciatica. 

More specifically, full psychedelic doses outperformed conventional medication, while microdoses delivered significantly better relief for migraines and comparable relief for the remaining conditions.

Microdosing psychedelics uk for pain relief 

The study builds upon the results from the Beckley Foundation and Maastricht Microdosing Research Programme, initiated in 2020 to investigate the effects of LSD microdoses on mood, cognitive function, and pain management. 

Notably, this earlier research demonstrated that a mere 20 microgram dose of LSD led to significant reductions in pain perception compared to a placebo.

Speaking to PsychedelicHealthUK, Amanda Feilding, Founder and Director of The Beckley Foundation, expressed optimism about the potential of microdosing psychedelics for chronic pain management, particularly in cases of migraine. 

With clinical research underway, it is her hope that migraine sufferers, who number one billion individuals globally each year, will soon gain legal access to these much-needed treatments.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart

You cannot copy content of this page